Introduction {#s02}
============

Bile acids (BAs) are a diverse group of amphipathic steroid molecules that enable micelle formation and facilitate intestinal absorption, emulsification, and transport of nutrients, lipids, and lipophilic vitamins. Recently, BAs were also recognized as a potent signaling molecules implicating pleiotropic physiological responses ([@bib32]; [@bib88]), which includes glucose and energy metabolism ([@bib87]; [@bib70]; [@bib78]). BAs are derived from catabolism of cholesterol in hepatocytes in a process that involves two principal pathways and activation of at least 17 hepatic enzymes. The classical pathway, which accounts for the majority of BA synthesis, is regulated by the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1). The alternative pathway involves an initial enzymatic step catalyzed by sterol-27-hydroxlase (CYP27A1), followed by BA hydroxylation by oxysterol 7α-hydroxylase (CYP7B1). Both pathways generate primary BAs that are actually the end products of cholesterol and are subsequently conjugated with taurine or glycine ([@bib3]; [@bib54]; [@bib115]).

Upon synthesis, BAs are secreted by hepatocytes and drained into the gallbladder via the biliary tree. Postprandial contraction of the gallbladder releases BAs to the duodenum. In the intestine, primary BAs can be deconjugated and 7α-dehydroxylated by the gut bacteria to form secondary BAs, leading to even higher heterogeneity in this group of molecules ([@bib63]; [@bib141]; [@bib36]; [@bib28]; [@bib58]; [@bib22]; [@bib129]). Intestinal BAs are actively reabsorbed in the terminal ileum and recirculated to the liver via the portal vein. In the liver, BAs are reconjugated and resecreted together with newly synthesized BAs. This efficient process, which allows recovery of the vast majority of BAs, is known as enterohepatic circulation ([@bib128]; [@bib4]).

A minor fraction of BAs escape the enterohepatic circulation, and these molecules are either excreted with the feces or reach the systemic circulation ([@bib1]). The latter enable activation of BA signaling outside the enterohepatic system, where they regulate a plethora of processes such as lipid and glucose homeostasis, energy expenditure, intestinal mobility, inflammation, configuration, and growth of the gut microbiome and even skeletal muscle mass ([@bib69]; [@bib55]; [@bib132]; [@bib42]; [@bib129]; [@bib8]). Dysregulated metabolism and signaling of BAs are suggested to play roles in several diseases, including dyslipidemia, fatty liver disease, diabetes, obesity, atherosclerosis, cholestasis, gallstones, and cancer ([@bib73]; [@bib9]; [@bib101]; [@bib80]). In this review, we will discuss the role of BAs in regulation of the glycemic control in health and in type 2 diabetes mellitus (T2DM). Other roles and functions of BAs are concisely discussed elsewhere ([@bib19]).

BA signaling and regulation of the glycemic response {#s03}
====================================================

Two main receptors, farnesoid X receptor FXR (also known as NR1H4) and the G protein--coupled BA receptor TGR5 (also known as GPBAR1, M-BAR, and BG37), mediate BA signaling. Other suggested BA receptors include vitamin D receptor (VDR; [@bib89]), pregnane X receptor (PXR; [@bib120]), sphingosine-1-phosphate receptor 2 (S1PR2; [@bib93]), muscarinic M2 receptor ([@bib119]), and constitutive androstane receptor (CAR; [@bib17]), which mainly regulate detoxification of the hepatotoxic species of BAs in addition to hepatic lipid and sterol metabolism.

FXR {#s04}
---

Both conjugated and nonconjugated BAs bind FXR, with chenodeoxycholic acid (CDCA) being the most potent agonist of this receptor ([@bib88]; [@bib95]; [@bib131]). FXR is ubiquitously expressed in tissues and organs, including the liver, gut ([@bib32]; [@bib117]), white adipose tissues ([@bib15]), and heart ([@bib142]), enabling BA-mediated regulation of different physiological functions.

FXR forms a heterodimer with retinoic X receptor (RXR), thereby suppressing the expression of CYP7A1, the rate-limiting enzyme in BA biosynthesis, leading to attenuated hepatic conversion of cholesterol to BAs. CYP7A1-dependent suppression by FXR is mediated by two mechanisms: (1) in the liver, FXR induces the expression of the small heterodimer partner (SHP), which in turn inhibits CYP7A1 expression; (2) in the gut, FXR increases the levels of circulating fibroblast growth factor 19 (FGF19; FGF15 in mice), which reduces the expression of CYP7A1 and cytochrome P450 12a-hydroxylase B1 (CYP8B1), leading to inhibition of BA synthesis ([Fig. 1](#fig1){ref-type="fig"}). The effects of intestinal FGF15/19 suppression on hepatic CYP7A1 and CYP8B1 are mediated by hepatic FGF4/βKlotho receptor (FGFR4/βKlotho; [@bib40]; [@bib53]; [Fig. 1](#fig1){ref-type="fig"}). Overexpression of CYP7A1 in obese mice causes weight reduction and protection from glucose intolerance, insulin resistance, dyslipidemia ([@bib82]), liver steatosis, inflammation, and fibrosis ([@bib85]), suggesting that hepatic expression of CYP7A1 alleviates metabolic derangements associated with obesity.

![**Regulation of BA synthesis by repression of Cyp7a1 is mediated by FXR signaling.** BA-FXR signaling in the liver activates SHP, which negatively controls Cyp7A1 expression. Intestinal BA-FXR signaling induces FGF15/19 expression. Release of intestinal FGF15/19 followed by binding of FGF15/19 to hepatic FGFR4/βKlotho leads to repression of hepatic Cyp7A1 and Cyp8B1.](JEM_20171965_Fig1){#fig1}

Postprandial activation of FXR in various organs leads to repression of gene expression by induction of SHP ([@bib40]) and suppression of autophagy by blocking both cAMP-response element--binding protein (CREB; [@bib116]) and peroxisome proliferator-activated receptor-α (PPARα) activation ([@bib77]). Furthermore, posttranslational modifications of FXR modulate its own activity, thus impacting lipid and glucose sensing in both the fed and fasting states. These include glucose-stimulated O-GlcNAcylation of FXR that enhances FXR activity ([@bib10]). The transcriptional activity of FXR is regulated by phosphorylation mediated by protein kinase C (PKC; [@bib37]) or adenosine monophosphate--activated protein kinase (AMPK; [@bib84]), and BA-FXR activation leads to enhanced FXR phosphorylation and proteasomal degradation of FXR ([@bib48]). FXR methylation supports the transactivation of FXR and FXR target genes ([@bib5]). In addition to methylation, acetylation increases FXR stability but inhibits FXR-RXRα dimerization, DNA binding, and transactivation activity and is regulated by p300 and Sirtuin-1 (SIRT1; [@bib64]). FXR acetylation is enhanced in mice models of obesity and T2DM ([@bib64]), and FXR acetylation exacerbates liver inflammation and glucose intolerance ([@bib65]).

Obese mice lacking FXR feature lower body weight coupled with an improved glycemic response and insulin sensitivity ([@bib104]; [@bib144]; [@bib109]). In contrast, lean mice lacking FXR display dyslipidemia associated with loss of insulin sensitivity and impaired glucose tolerance ([@bib87]). Long-term oral supplementation of FXR agonist (GW4064) to obese and insulin-resistant mice led to exacerbated weight gain, dyslipidemia, and glucose intolerance ([@bib135]). It is important to note that this effect was different from the improved insulin sensitivity that was observed upon short-term treatment with this agonist ([@bib15]). Collectively, whole-body manipulation of FXR affects different tissues leading to complex alterations in glucose and energy homeostasis.

Hepatic BA-FXR signaling modulates postprandial glucose levels through decreased liver gluconeogenesis accompanied by induction of hepatic glycogen synthesis ([@bib25]; [@bib143]; [@bib102]; [Fig. 2](#fig2){ref-type="fig"}). Mice studies showed that after eating, induction of BAs secretion results in BA-FXR signaling in the liver, leading to stimulation of glycogen storage and inhibition of hepatic glycolytic and lipogenic gene expression, such as carbohydrate responsive element--binding protein (ChREBP) and sterol responsive element--binding protein 1 (SREBP1c; [@bib133]; [@bib25]; [@bib87]; [Fig. 2](#fig2){ref-type="fig"}). Further studies in mice showed that FXR signaling in the liver causes repression of enzymes involved in hepatic gluconeogenesis including phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase; [@bib143]; [@bib102]; [Fig. 2](#fig2){ref-type="fig"}). However, the underlying mechanism governing FXR control of hepatic gluconeogenesis remains elusive and requires further investigation in both the fasting and postprandial state. Interestingly, several mice studies suggest that FXR signaling does not directly affect liver insulin sensitivity, but rather impacts peripheral insulin sensitivity in tissues such as adipose tissue and skeletal muscle ([@bib15]; [@bib87]). A recent study by Kim et al. ([@bib67]) reported that hepatic deletion of both FXR and SHP improves glucose tolerance and fatty acid metabolism in aged mice, reversing the aging phenotype of increased adiposity and impaired glucose sensing. This supports a key role of hepatic FXR-SHP signaling in controlling whole-body glucose and energy homeostasis.

![**BA signaling controls the systemic glycemic response.** In the liver BA-FXR signaling inhibits gluconeogenesis and promotes glycogen synthesis by negative regulation of PEPCK, G6Pase, and ChREBP. In intestinal L cells, BA-TGR5 signaling leads to GLP-1 expression and secretion, whereas BA-FXR signaling inhibits GLP-1 production. The gut microbiome controls BA diversity, whereas BA composition mediates gut microbiome configuration. In the brain, BA-TGR5 signaling mediates satiety. In skeletal muscles and brown adipose tissue, BA-TGR5 sensing promotes T4 conversion to T3, leading to increased energy expenditure. In the pancreas, both BA-TGR5 and BA-FXR signaling in β cells induces insulin production. Glucose-stimulated insulin release is additionally promoted by BA-TGR5 signaling in α cells, which causes conversion of proglucagon to GLP-1 and GLP-1 release. TGR5-BA in immune cells results in inhibition of NLRP3-inflammasome and attenuated inflammation. CCL, chemokine (C-C motif) ligand; Dio2, type 2 iodothyronine deiodinase; LIP, liver inhibitory protein; T4, thyroxine; T3, tri-iodothyronine.](JEM_20171965_Fig2){#fig2}

BA-FXR--mediated induction of intestinal FGF15/19, leads to its binding to hepatic FGFR4/βKlotho, thereby contributing to hepatic glycogen synthesis and decreasing glycemia ([Fig. 2](#fig2){ref-type="fig"}; [@bib68]). As such, FGF15 deficient mice featured hyperglycemia and impaired hepatic glycogen synthesis, which was ameliorated by FGF19 administration, suggesting a beneficial effect of FGF15/19 on energy and glucose metabolism ([@bib68]). In concert, systemic administration of FGF19 to obese and diabetic mice induced an anti-diabetic effect ([@bib33]). Similarly, a positive association between FGF19 and improved insulin sensitivity was demonstrated in T2DM patients who achieved normoglycemia as a result of a bariatric surgery Roux-en-Y gastric bypass (RYGB; [@bib110]). Several downstream mechanisms have been suggested to explain the beneficial metabolic effects of FGF15/19, including inhibition of hepatic gluconeogenesis by modulating G6Pase and PEPCK ([@bib102]) and stimulation of insulin-independent glycolysis in the brain ([@bib91]). Additional mechanism for FGF19 function in the brain was demonstrated by Ryan et al. ([@bib108]), who administered FGF19 by intra-ventricular injection into the central nervous system of mice. This resulted in anorexigenic effect, weight loss and improved glucose metabolism, which were blunted by FGF19 inhibition, suggesting a role of FXR signaling in the satiety response ([Fig. 2](#fig2){ref-type="fig"}). Furthermore, recent study by [@bib100] revealed that FGF15 expression in the hypothalamus negatively regulates dorsal vagal complex neuronal activity, ultimately leading to lower glucagon secretion from pancreatic α cells. Collectively, these results suggest that intestinal, hepatic and neuronal activation of FGF15/19 provides a network of signals leading to systemic control of the glycemic response in normoglycemia and in T2DM ([Fig. 2](#fig2){ref-type="fig"}).

Several recent studies highlight an additional effect of FXR signaling in the gastrointestinal tract. Blocking intestinal FXR had a beneficial effect on glucose homeostasis and energy expenditure. In the intestine, FXR signaling improves the kinetics of glucose 6-phosphate (G6P) absorption, an affect which was mitigated in FXR-deficient mice ([@bib127]). Mice with an isolated intestinal deficiency of FXR displayed protection from development of obesity and glucose intolerance ([@bib81]; [@bib57]), suggesting a central role of intestinal FXR in driving obesity-associated pathologies. In agreement with these findings, several studies ([@bib81]; [@bib56],[@bib57]; [@bib139]) showed that obese and diabetic mice treated with intestinal FXR antagonists develop a significant reduction in glucose intolerance, insulin resistance, fatty liver as well as elevated energy expenditure because of lower intestinal and total ceramide levels. Recently, [@bib139] reported that lower ceramide levels induced by blocking intestinal FXR led to attenuated hepatic gluconeogenesis by lowering liver mitochondrial acetyl-CoA levels and pyruvate carboxylase activity, thus adding another possible mechanism linking intestinal FXR signaling with hepatic regulation of gluconeogenesis. In contrast to studies presenting improved metabolic outcomes upon treatment with intestinal FXR antagonist or in mice lacking intestinal FXR, [@bib29] showed that the administration of intestinal FXR agonist fexaramine to obese and diabetic mice reduced weight gain, glucose intolerance and insulin resistance along with increased energy expenditure. However, the metabolic phenotype shown with fexaramine was abrogated in mice lacking TGR5, suggesting that this drug may partially regulate TGR5 signaling in addition to FXR signaling. Collectively, most studies demonstrate that activation of intestinal FXR has a detrimental effect on the glycemic response and energy expenditure in response to obesity, suggesting that inhibition of intestinal FXR signaling has a potential for treating hyperglycemia. Additional mechanisms of intestinal FXR signaling and its outcomes merit further studies, including possible effects on glucose turnover and G6P absorption ([@bib127]).

TGR5 {#s05}
----

TGR5 is a G protein--coupled receptor expressed in many organs and tissues including the intestine, gallbladder, brown and white adipose tissues, skeletal muscle, brain and the pancreas. BA activation of TGR5 leads to cAMP production, which in turn activates protein kinase A (PKA) pathways in different tissues and cell types ([@bib62]; [@bib61]).

Activation of TGR5 by BAs promotes glucagon like peptide-1 (GLP-1) secretion from intestinal L cells ([Fig. 2](#fig2){ref-type="fig"}). This peptide acts on the pancreatic β cells and regulates glucose-stimulated insulin secretion ([@bib61]; [Fig. 2](#fig2){ref-type="fig"}). TGR5 signaling in intestinal L cells was suggested to induce mitochondrial oxidative phosphorylation, a rise in the ATP/ADP ratio, subsequent closure of the ATP-dependent potassium channel (KATP) and enhanced mobilization of intracellular calcium, leading to GLP-1 secretion and improvement in glucose homeostasis ([@bib124]). [@bib125] found that GLP-1 secretion by intestinal L cells is negatively regulated by FXR through inhibition of pro-glucagon gene expression and suppression of GLP-1 secretion ([Fig. 2](#fig2){ref-type="fig"}). These results suggest that BA activation of both TGR5 and FXR in intestinal L cells can induce opposite effects on GLP-1 secretion and production. However, TGR5 activation in L cells likely occurs rapidly after food ingestion, whereas activation of FXR induces a more delayed response that requires transcriptional activation. This difference leads to a temporal separation between postprandial positive effects of BA-TGR5 signaling on GLP-1 secretion and FXR-mediated inhibition of GLP-1 release ([@bib125]; [Fig. 2](#fig2){ref-type="fig"}). In accordance, several studies reported that T2DM patients who achieved normoglycemia as a result of RYGB bariatric surgery, featured a marked increase in fasting and postprandial BAs. The change in BA levels positively correlated with FGF19, GLP-1 and PYY ([@bib26]; [@bib110]), but no causative relationship between BA-TGR5 signaling and incretin levels was pursued in these patients.

Mice overexpressing TGR5 that were fed a high-fat diet (HFD) featured improved glucose-stimulated insulin secretion compared with wild-type mice, and similar results were reported in obese and diabetic mice treated with TGR5 agonists exhibiting reduced hepatic glucose production ([@bib124]). Conversely, TGR5-deficient mice displayed glucose intolerance and impaired insulin secretion in response to obesity ([@bib124]) that were abrogated by the administration of TGR5 agonists ([@bib98]; [@bib13]). In light of the beneficial effects of TGR5 signaling, a substantial reduction in hyperglycemia and elevated GLP-1 was observed in a small group of T2DM patients who received a high dose of the TGR5 agonist SB-756050 ([@bib51]). However, studies in rodents show that the effect of systemic exposure to TGR5 agonists increases gallbladder volume ([@bib13]). Thus, an ideal TGR5 agonist would be intestinal-specific agonist reaching L cells without affecting other systemic tissues. Indeed, [@bib76] recently described a novel topical intestinal agonist of TGR5 that was given orally to obese and insulin-resistant mice, leading to prominent elevation in GLP-1 levels along with significant improvement in glucose tolerance. Intestinal TGR5 agonist did not cause a significant change in gallbladder size in lean mice. The impact of intestinal TGR5 agonist on human gallbladder and its therapeutic potential for T2DM in humans requires further study.

In addition to GLP-1 modulation, TGR5 can induce cAMP-dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase, causing elevated energy expenditure in brown adipocytes and skeletal muscles. This is achieved by converting inactive thyroxine (T4) into active tri-iodothyronine (T3) that critically determinates thyroid hormone receptor regulation of energy expenditure ([@bib134]; [Fig. 2](#fig2){ref-type="fig"}). In concert with the results in rodents, [@bib97] found that obese individuals who undergo RYGB had elevated levels of BAs that were inversely correlated with thyroid-stimulating hormone (TSH) levels compared with nonoperated obese controls. However, the mechanism of action of BAs on TSH production remains unknown.

Another mechanism possibly connecting BA signaling and elevated energy expenditure was proposed recently by [@bib137]. They showed that cold exposure in mice triggered cholesterol lipoprotein uptake in brown adipose tissue and hepatic *Cyp7b1* expression. This led to BA catabolism from cholesterol by the alternative pathway, which in turn caused modifications in the gut microbiome that facilitated adaptive thermogenesis. The authors observed lower hepatic expression of *Cyp7b1 in* obese patients with T2DM ([@bib137]), but the clinical relevance of cold-induced BA synthesis remains unknown. Interestingly, oral supplementation of the BA CDCA to women led to increased brown adipose tissue activity and glucose uptake accompanied with increased energy expenditure, but the mechanism involved in BA stimulation of brown adipose tissue activity in humans is unclear ([@bib14]).

Pancreatic β cells express both TGR5 ([@bib74]) and FXR ([@bib107]), promoting glucose-stimulated insulin secretion by increasing intracellular calcium concentration ([Fig. 2](#fig2){ref-type="fig"}). FXR additionally mediates the induction of insulin transcription ([@bib107]). As mentioned in the FXR section, FXR-deficient mice are protected from obesity-induced glucose intolerance. Similar insulin levels and pancreatic islet mass were observed in obese mice lacking FXR and wild-type mice, suggesting that the protection from obesity and glucose tolerance that was found in FXR-deficient mice cannot be explained merely by compensation through enhanced β cell insulin secretion ([@bib114]). Interestingly, pancreatic α cells also express TGR5. Activation of TGR5 by BA switches the α cell secretory phenotype from glucagon to GLP-1, thus promoting a paracrine effect on β cells to stimulate insulin secretion ([@bib75]; [Fig. 2](#fig2){ref-type="fig"}).

Collectively, manipulating FXR and TGR5 signaling in rodents and humans plays pivotal roles in regulating glucose metabolism via signaling in different organs ([Fig. 2](#fig2){ref-type="fig"}). In most studies, intestinal FXR activation causes deleterious effects on hyperglycemia, whereas TGR5 signaling improves glycemic control and energy homeostasis. Consequently, activation of TGR5 signaling coupled with blocking intestinal FXR may serve as an innovative approach for controlling the glycemic response in T2DM patients. However, the tissue-specific functions and the long-term effects of FXR and TGR5 signaling in different environmental conditions such as different diets and nutritional states, which modulates systemic glucose control, merits further investigation.

Factors regulating the BA pool {#s06}
==============================

Several factors influence BA concentration and consequently BA-FXR and TGR5 signaling ([Fig. 2](#fig2){ref-type="fig"}). First, the concentration of BAs depends on food transit time. As such, BA pools are higher in the postprandial in comparison with the fasting state ([@bib4]; [@bib83]; [@bib45]). This is a result of enhanced postprandial BAs secretion into the small intestine, increased enterohepatic reabsorption, and, possibly, enhanced transcription and activity of hepatic CYP7A1 ([@bib83]). Second, obesity impacts the BA pool ([Fig. 2](#fig2){ref-type="fig"}). In response to a mixed meal, obese subjects feature slightly higher circulating levels of BAs ([@bib45]). More specifically, other studies showed that the changes in BA levels observed in obese subjects include alterations in the BA ratio and blunted excursion of glycine-conjugated BAs compared with lean subjects ([@bib38]; [@bib2]; [@bib45]). The difference in BA composition between lean and obese subjects can be partially explained by the reduced expression of some hepatic BA transporters, coupled with an increase in 12-α hydroxylated BA synthesis ([@bib45]). Third, insulin and glucose significantly alter BA composition and abundance ([Fig. 2](#fig2){ref-type="fig"}). Mice treated with streptozotocin to induce hyperglycemia or obese and diabetic mice display elevated serum levels of BAs and a larger BA pool. This effect could be mediated by induction of *Cyp7a1* mRNA expression by increased acetylation and decreased methylation of the *Cyp7a1* gene promoter ([@bib83]). Consistent with the results in rodents, humans undergoing oral glucose tolerance testing showed increased levels of several BAs ([@bib118]). An euglycemic-hyperinsulinemic clamp study in humans found that insulin acutely caused a significant reduction in circulating BAs and that this effect was blunted in obese subjects ([@bib45]). In humans, elevated levels of 12-hydroxylated BAs were associated with insulin resistance ([@bib44]). [@bib43] investigated the mechanism for this difference in the BA pool and found that in mice with normal physiology, insulin signaling activating FoxO1 maintains the production of 12-hydroxylated BAs by up-regulation of Cyp8b1 and normal FXR activity. In obese and insulin-resistant mice, the impaired insulin and FoxO1 signaling leads to an excess of 12-hydroxylated BAs. Fourth, the daily circadian rhythm influences the BA pool, leading to a significant increase after feeding ([@bib34]; [@bib79]; [Fig. 2](#fig2){ref-type="fig"}). In mice, these diurnal changes seem to be regulated by the transcription of *Cyp7a1* ([@bib79]), by the clock gene Rev-erbα ([@bib24]), and by *Fgf15* ([@bib46]). Finally, sex hormones were suggested to affect BA metabolism, but controversial findings have been reported on the differences in baseline fasting BA levels between men and women ([@bib35]; [@bib50]; [@bib7]).

BAs and the gut microbiome {#s07}
==========================

The gut microbiome plays key roles in BA synthesis, modification, and signaling by transforming host-derived primary BAs into secondary BAs and by their deconjugation (e.g., removal of glycine or taurine) via the enzymatic activity of bile salt hydrolases ([@bib123]). Mice treated with antibiotics or germ-free mice displayed a predominance of primary BAs with a reduced secondary BA pool, suggesting a central role of the gut microbiome in generating BA diversity. The lower BA diversity in microbiome-depleted mice is accompanied by enhanced hepatic expression of CYP7A1 and reduced ileal expression of FGF15 and SHP ([@bib112]; [@bib129]). These differences in gene expression were abrogated upon colonization of germ-free mice with bacteria ([@bib130]). [@bib112] showed that BA diversity is controlled by the gut microbiome in an FXR-dependent manner and that it affects the synthesis of primary BAs by regulating FGF15 and CYP7A1 expression along with conjugation and absorption of BAs. Moreover, several studies suggested that BAs may directly affect bacterial composition, creating a dynamic equilibrium between BAs and the gut microbiome composition and function ([@bib55]; [@bib60]; [Fig. 2](#fig2){ref-type="fig"}).

BA-FXR signaling and the associated modification in microbiome composition may be clinically relevant, because the beneficial effects of bariatric surgery on glucose and body weight are also associated with changes in the gut microbial communities and are FXR dependent ([@bib109]; [@bib96]). Further investigation of the interactions between the gut microbiome and BA signaling, as well as their impact on glycemic control, may help to identify whether supplementation with certain BAs can change the microbiome configuration and therefore be used as a treatment for hyperglycemia. Studying the microbiome--BA axis may additionally lead to the identification of bacterial species that modulate BA signaling in a way that would enable targeted probiotics ([@bib21]) or prebiotics to improve the glycemic response in diabetic patients.

BAs and regulation of inflammation {#s08}
==================================

Inflammation is another mechanism that could be involved in BA regulation of the glycemic response, because chronic low-grade inflammation is suggested to play a role in glucose homeostasis ([@bib83]). Studies in murine models and primary hepatocytes show that obeticholic acid (OCA) induced an anti-inflammatory response mediated by inhibition of NF-κB activity leading to reduced expression of proinflammatory cytokines ([@bib85]), but there are controversial studies on the effect of OCA on insulin sensitivity in T2DM patients ([@bib92]; [@bib94]). Inflammasomes are cytoplasmic innate immune protein complexes activated by both pathogens and endogenous tissue damage--related signals and have been suggested to play key roles in regulation of obesity and the glycemic response ([@bib126]; [@bib49]; [@bib106]). Upon activation by one of a variety of different signals, NOD-like receptors (NLRs) form mature inflammasome complex. This results in activation of proinflammatory caspase, processing of mature cytokines such as IL-1β and IL-18, and a controlled cell death termed pyroptosis ([@bib106]). Several studies showed that TGR5 induces an anti-inflammatory response in myeloid cells by suppressing proinflammatory cytokines ([@bib132]; [@bib52]; [@bib99]). [@bib99] showed that in response to diet-induced obesity, wild-type mice transplanted with TGR5^−/−^ bone marrow or mice with myeloid-specific deletion of TGR5 displayed exacerbated glucose intolerance, insulin resistance, and adipose tissue inflammation. Bone marrow--derived macrophages isolated from TGR5-depleted mice exhibited a significant reduction in LPS-induced chemokine expression and macrophage migration that was mediated by AKT-dependent activation of mTOR and CCAAT/enhancer binding protein β (C/EBP β). In concert, other studies ([@bib101]; [@bib132]; [@bib52]; [@bib41]; [@bib122]) showed that TGR5 activation inhibits LPS induction of proinflammatory cytokines and NF-κB phosphorylation and signaling, which was ablated in TGR5-deficient mice. Altogether, these studies suggest that TGR5 activation may decrease systemic inflammation and macrophage infiltration to adipose tissues that may possible lead to improved glucose and insulin sensitivity in obesity ([Fig. 2](#fig2){ref-type="fig"}). In line with the role of TGR5 in attenuated inflammation, [@bib42] demonstrated that BA-TGR5 signaling induces inhibition of the NLRP3 inflammasome, which in turn improved insulin sensitivity and glucose tolerance, suggesting a possible link between BA-TGR5 signaling in innate immune cells and metabolic functions ([Fig. 2](#fig2){ref-type="fig"}). Future studies will lead to mechanistic understanding of the interaction between BA signaling and immune cells and their effects on inflammation and glucose metabolism in health and in T2DM.

Clinical relevance of BA signaling in glycemic control {#s09}
======================================================

T1DM {#s10}
----

The clinical impact of BAs on hyperglycemia and diabetes mellitus was almost exclusively investigated in studies focusing on T2DM in rodents and humans, as highlighted below. In contrast, the contribution of BAs to the pathogenesis of type 1 diabetes mellitus (T1DM) remains less characterized. A model for T1DM involves treatment of mice with streptozotocin, a drug exhibiting high toxicity to insulin-producing β cells. Upon development of T1DM in this model, mice display a significant rise in total BA level in serum, gallbladder and intestine while featuring lower levels of secondary BAs in the gallbladder and in the feces ([@bib83]). Similarly, children with T1DM (even when well controlled) harbor alterations in urine and serum BA composition compared with healthy controls ([@bib6]). Likewise, adults with well or poorly controlled T1DM showed an altered profile of circulating BAs in comparison to healthy adults ([@bib27]). Collectively, these studies suggest that alterations in BA composition in T1DM persist even after induction of normoglycemia, suggesting a potential yet unproven causal association between altered BA profile and the progression of T1DM that requires further study.

T2DM {#s11}
----

The contribution of BAs to the regulation of glycemic responses in T2DM was mainly demonstrated through the effects of BA sequestrants ([Fig. 3](#fig3){ref-type="fig"}) and the effects demonstrated in patients undergoing bariatric surgery, which dramatically impacts both glucose levels and BA profile.

![**BAs and diabetes mellitus.** Impaired BA signaling in the context of an altered glycemic response contributes to progression toward T2DM through multiple mechanisms.](JEM_20171965_Fig3){#fig3}

BA sequestrants are orally administered nonabsorbable resins that lack systemic toxicity and have been used for treatment of dyslipidemia ([@bib31]). Unexpectedly, BA sequestrants have beneficial effects on the glycemic control and insulin sensitivity in T2DM patients and diabetic rodents ([@bib47]). Hence, one BA sequestrant, colesevelam, is a US Food and Drug Administration--approved drug used to treat diabetes. T2DM patients treated for 12 weeks with colesevelam showed a significant reduction in HbA1c and postprandial glucose levels ([@bib146]), even when colesevelam was given in combination with other antidiabetic drugs ([@bib31]), whereas healthy insulin-sensitive subjects remained unaffected by colesevelam treatment ([@bib12]). Some T2DM patients treated with colesevelam exhibited an increase in plasma triglyceride levels, which precludes colesevelam treatment in T2DM subjects with hyperglyceridemia ([@bib31]). Obese and diabetic mice treated with colesevelam showed improved glycemic response mediated by a dual mechanism: (1) TGR5-mediated GLP-1 secretion in L cells and (2) intestinal proglucagon expression ([@bib103]; [@bib125]). The beneficial metabolic effects of colesevelam were also dependent on FXR signaling because FXR deletion diminishes the effect of the drug ([@bib104]; [@bib125]). Hypothetically, and similarly to BA sequestrants, future drugs impacting BA signaling may serve as future modalities for T2DM treatment.

Multiple studies in humans ([@bib136]; [@bib113]) and rodents ([@bib71]) demonstrated the efficacy of bariatric surgery in improving and even normalizing blood glucose levels in T2DM. The improvement in the glycemic response is observed much earlier than weight loss ([@bib136]), suggesting weight-independent beneficial effects of the surgery on glucose metabolism ([@bib86]). Interestingly, bariatric surgery also influences BA metabolism and disrupts the enterohepatic circulation, thereby leading to a rise in BA levels ([@bib2]). The mechanisms for the increase in BAs upon bariatric surgery are currently unclear and may include induction of BA reabsorption in the ileum with an opposite decrease of reabsorption in the liver after bile diversion ([@bib11]; [@bib39]), blunted hepatic glucose production, an increase in intestinal gluconeogenesis ([@bib39]), and changes in gut microbial communities ([@bib109]). Other mechanisms that control BA pool upon bariatric surgery include modified activation of FXR and TGR5 signaling ([@bib109]; [@bib23]; [@bib90]). Alterations in BA pool were proposed to constitute one of the mechanisms that positively affect glucose metabolism after bariatric surgery ([@bib30]). Obese FXR-deleted mice that undergo bariatric surgery exhibit impaired weight loss and glucose tolerance improvement ([@bib109]), suggesting that BA-FXR signaling may govern weight and glucose control after bariatric surgery. Nevertheless, studies on the composition of the circulating BAs after bariatric surgery are inconsistent because of different measurement methods, lack of adjusted control groups, a focus on some (but not all) BAs in different human studies, and differences in surgical procedures between cohorts ([@bib18]; [@bib20]; [@bib26]; [@bib110]). Additionally, several studies that followed T2DM subjects before and after RYGB showed that the changes in glucose tolerance and insulin sensitivity preceded the rise in BAs ([@bib121]; [@bib59]), pointing toward the possibility that the increase in BAs in the circulation after RYGB may not drive changes in the glycemic response but rather may constitute a secondary effect. Collectively, at present, the contribution of BAs to the regulation of glucose metabolism upon bariatric surgery remains unclear, with no clear-cut causative evidence linking postbariatric BA alterations with the postsurgical improvement in glucose control.

Another therapeutic approach for hyperglycemia and T2DM that manipulates BA levels involves inhibition of apical sodium-dependent bile acid transporter (ASBT). ASBT is expressed in the distal ileum and has an important role in BA reabsorption in the lumen of the small intestine, which is pivotal for enterohepatic recirculation. ASBT inhibitors reduce ileal BA absorption and induce BA excretion in the feces. In the liver, ABST inhibitors stimulate BA production by induction of Cyp7a1 and Cyp8b1 and suppression of Fgf15 expression in the ileum ([@bib105]). Importantly, ASBT inhibitors improve insulin sensitivity and reduce hyperglycemia and elevated incretin levels in rodent models of diabetes ([@bib16]; [@bib138]) and diet-induced obesity and glucose intolerance ([@bib105]). Further studies are required to determine the efficacy and safety of ASBT inhibitors in patients with T2DM.

Challenges and future perspectives {#s12}
==================================

The knowledge gained from observations in mice and humans enhances our understanding that some BAs may play important roles in regulating the glycemic response in health and in T2DM. Mechanisms for these effects are diverse, as BA-FXR and TGR5 signaling modulates incretin excretion, hepatic glucose homeostasis, inflammation, energy expenditure, all of which have been convincingly shown to exert major implications on glucose and energy metabolism. Furthermore, the cross-talk between BAs and the gut microbiome leads to cross-regulation of both BAs and microbiome composition, the balance of which may impact the glycemic response. Thus, impaired BA signaling along with associated dysbiosis may contribute to T2DM and other metabolic complications associated with obesity ([Fig. 3](#fig3){ref-type="fig"}).

However, major challenges limit our understanding of BA contribution to the glycemic response in human health and disease. One major limitation relates to the fact that mice and humans are inherently different in many aspects related to BA biology. For example, mice and humans have different BA compositions, potentially leading to different physiological effects and interventional outcomes in respective studies. For example, mice produce the potent FXR antagonist tauro-β-muricholic acid (T-β-MCA), which is resistant to bacterial bile salt hydrolase and thus can maintain intestinal stability and serve as an intestinal FXR antagonist. As such, oral administration of a T-β-MCA derivative, glycine-β-muricholic acid (Gly-MCA), decreased murine FXR signaling in the ileum, resulting in improved obesity, insulin resistance, and liver steatosis associated with lower serum levels of ceramides ([@bib56],[@bib57]). In contrast, humans cannot produce T-β-MCA and instead bear CDCA and cholic acid (CA) as their predominant BAs. These molecules may mediate different downstream effects than those seen in rodents. Another example of such functional interspecies variation includes the preferential induction in mice of intestinal FGF15 in response to FXR activation in contrast to a preferential induction of FGF19 in response to the same stimulus in humans. Thus, extrapolation of results obtained in mouse-based FGF15 studies to humans should be performed with caution. Even more generally, translation of mouse-based findings suggesting regulatory roles of BAs in glycemic responses may not necessarily translate to humans.

Additional limitations are related to the inherent variability in the composition and function of the gut microbiome in humans. This results in varying and highly person-specific BA profiles, which differentially impact disease pathogenesis and possibly the response to BA-associated medical interventions.

With those limitations and challenges notwithstanding, the use of synthetic antagonists of intestinal FXR ([@bib15]; [@bib87]; [@bib104]; [@bib81]; [@bib57]; [@bib139]) and agonists of TGR5 ([@bib134]; [@bib124]; [@bib74]; [@bib13]; [@bib29]; [@bib51]) showed promising preliminary results in improving glycemic control in obese and diabetic rodents. Intestinal FXR antagonists attenuated hepatic gluconeogenesis and lowered intestinal and serum ceramides, whereas TGR5 agonists promoted GLP-1 secretion from L cells and activated thermogenesis in brown adipocytes. Hence, an ideal treatment for hyperglycemia may combine intestinal-specific FXR antagonists, which would prevent undesirable effects stemming from hepatic FXR signaling, with TGR5 agonists. This tissue restriction is important because mice featuring a full-body deletion of FXR developed a high incidence of hepatic cancers ([@bib66]; [@bib140]), whereas mice featuring a liver-specific deficiency of FXR exhibited increased cholic acid--induced liver tumors ([@bib72]). TGR5 activation can be developed for T2DM treatment in rodents and humans ([@bib51]), but a systemic TGR5 agonist may increase gallbladder volume ([@bib13]). Accordingly, an optimal intestine-specific TGR5 agonist would be able to induce secretion of incretins from L cells without producing other systemic adverse effects. Unfortunately, restricting TGR5 activation to the gut would impede the beneficial effects of TGR5 on energy metabolism in brown adipose tissue. Collectively, developing intestinal-specific FXR antagonists and TGR5 agonists may constitute a promising future approach for hyperglycemia treatment. A cautionary note is that the long-term effects of blocking intestinal FXR and activation of TGR5 in T2DM patients merit future evaluation.

FGF19 represents another potential BA-related therapeutic target. It is increasingly evident that intestinal induction of FGF19 by FXR signaling is positively correlated with glucose homeostasis ([@bib33]; [@bib68]; [@bib110]). Moreover, FGF19 administration to obese and diabetic mice improved the glycemic response ([@bib33]), whereas FGF19 was elevated in T2DM subjects after the achievement of normoglycemia ([@bib110]). Together, this indicates that FGF19 induction may potentially serve as a novel therapeutic modality contributing to glycemic control in T2DM. However, FGF19 expression can also promote hepatocellular carcinoma ([@bib111]). Designing FGF19 analogues that retain the intestinal BA regulatory activity without promoting hepatic carcinogenesis ([@bib145]) could potentially improve glycemic control in diabetic patients while maintaining an adequate safety profile.

Collectively, the effect of BAs on metabolic functions is highly complex and tightly regulated, yet therapeutic approaches targeting BA signaling hold promise in contributing to improved glycemic responses in patients with T2DM and potentially in T1DM. The major challenge is the development of a drug that manipulates BA signaling in a tissue-specific manner that can significantly normalize the glycemic response without causing significant adverse effects. Such intervention may potentially contribute to the treatment and prevention of a variety of chronic metabolic syndrome--related diseases.
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